Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma.
Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma.
复制标题
DOI：
10.21037/apc.2020.03.03
复制
发表时间：
2020-07-01
期刊：
影响因子：
--
通讯作者：
Zheng, Lei
中科院分区：
文献类型：
--
作者：
He, Mengni;Henderson, MacKenzie;Zheng, Lei
胰腺导管腺癌（PDAC）由于诊断晚、治疗手段有限、预后差，迫切需要更好的诊断和治疗方法。寻找合适的动物模型来概括肿瘤分子发病机制和肿瘤微环境（TME）的复杂性对于临床前免疫治疗和非免疫治疗的发展至关重要。本文综述了目前流行的临床前动物模型，包括患者来源的异种移植模型、人源化小鼠模型、基因工程小鼠模型和同基因小鼠模型。通过比较这些模型在不同的研究环境中，我们希望在寻找最相关的临床前模型，以适应各种研究目的提供指导。
Pancreatic ductal adenocarcinoma (PDAC) is in urgent need of better diagnostic and therapeutic methods due to its late diagnosis, limited treatment options and poor prognosis. Finding the right animal models to recapitulate the tumor molecular pathogenesis and tumor microenvironment (TME) complexity is critical for preclinical immunotherapeutic and non-immunotherapeutic treatment developments. In this review, we summarize and evaluate popular preclinical animal models including patient-derived xenograft models, humanized mouse models, genetically engineered mouse models, and syngeneic mouse models. Through comparisons between these models in different research settings, we hope to provide guidance in finding the most relevant preclinical models to suit various research purposes.